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A B S T R A C T
Recommendations for specimen collection and handling have been developed for adoption across
breast cancer clinical trials conducted by the Breast International Group (BIG)-sponsored Groups and
the National Cancer Institute (NCI)-sponsored North American Cooperative Groups. These recommen-
dations are meant to promote identifiable standards for specimen collection and handling within and
across breast cancer trials, such that the variability in collection/handling practices that currently exists
is minimized and specimen condition and quality are enhanced, thereby maximizing results from
specimen-based diagnostic testing and research. Three working groups were formed from the
Cooperative Group Banking Committee, BIG groups, and North American breast cancer cooperative
groups to identify standards for collection and handling of (1) formalin-fixed, paraffin-embedded (FFPE)
tissue; (2) blood and its components; and (3) fresh/frozen tissue from breast cancer trials. The working
groups collected standard operating procedures from multiple group specimen banks, administered a
survey on banking practices to those banks, and engaged in a series of discussions from 2005 to 2007.
Their contributions were synthesized into this document, which focuses primarily on collection and
handling of specimens to the point of shipment to the central bank, although also offers some
guidance to central banks. Major recommendations include submission of an FFPE block, whole
blood, and serial serum or plasma from breast cancer clinical trials, and use of one fixative and
buffer type (10% neutral phosphate-buffered formalin, pH 7) for FFPE tissue across trials.
Recommendations for proper handling and shipping were developed for blood, serum, plasma,
FFPE, and fresh/frozen tissue.
J Clin Oncol 26:5638-5644. © 2008 by American Society of Clinical Oncology
INTRODUCTION AND PURPOSE
The Breast International Group (BIG) and the
North American Cooperative Groups encompass
breast cancer clinical trials groups (“groups”) from
across the world. The European-based BIG con-
ducts major, multicenter trials in breast cancer
across groups based in Europe, Australasia, Latin
America, and Canada. In North America, major
group clinical trials in breast cancer are performed
by the Breast Cancer Intergroup of North America
(TBCI), which unifies the efforts of several breast
cancer research groups, and the National Surgical
Adjuvant Breast and Bowel Project (NSABP); the
Radiation Therapy Oncology Group (RTOG)
conducts research in several cancers, including
breast cancer, with a focus on radiation oncology.
Thus, research conducted by BIG and the North
American groups spans a large number of sites
across the world, as well as a wide range of treat-
ment modalities.
In 2005, BIG approached the North American
breast cancer cooperative groups to initiate more
in-depth discussions between these two major
networks of breast cancer research groups. The
following goals were determined for this interna-
tional collaboration: (1) early sharing of trial designs
for drugs and strategies; (2) discussion of combined
analyses, where appropriate; (3) early sharing of
ideas about translational research projects; and (4)
collaboration on translational research projects.
During their first meeting, both sets of groups
agreed that a strong need existed for identifiable
standards for the collection and handling of speci-
mens from group breast cancer clinical trials. This
article, one of the first major efforts of the collabora-
tion, was developed to identify and elucidate such
a standard.
Variable methods of collection, processing, and
storage of clinical trial biospecimens across these
groups have resulted in variability of specimen con-
dition and quality as well as subsequent research
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results. Indeed, data demonstrate that upfront handling and process-
ing of specimens, including formalin-fixed, paraffin-embedded
(FFPE) tissue has a significant impact on the quality of intercellular
and intracellular components, which may affect results of analyses
performed on those specimens.1-5
We hope that the following standards, or guidelines, will help to
ensure an acceptable level of quality in group clinical trial specimens,
both for research and diagnosis, and will enhance the reproducibility
and comparability of test results derived from them. Given the high
level of annotation that typifies clinical trial specimens, including
outcome data as well as the relatively uniform treatments adminis-
tered across cohorts of clinical trial patients, clinical trial specimens are
indeed valuable to cancer research, particularly translational research.
Specifically, these guidelines were developed to provide a set of
consensus procedures for the collection and handling of (1) blood and
blood components (cells, serum, and plasma), (2) FFPE tissue, and (3)
fresh/frozen tissue biospecimens collected from BIG and North
American group breast cancer clinical trials. They focus primarily on
specimen collection and processing to the point of specimen shipment
to the central bank. Therefore, procedures discussed are mostly in-
tended for procurement sites, as opposed to central banks and inves-
tigators processing and analyzing the specimen, although some
guidance on those points is also provided.
These guidelines are not expected to be a comprehensive report
for all biospecimen collection, processing, storage, distribution, and
repository operations. For additional guidance, we refer readers to
the National Cancer Institute Best Practices for Biospecimen Re-
sources6 (these guidelines are also referenced at http://ctep.cancer
.gov/guidelines/spec_bc_grptrials.html).
OVERARCHING AIMS OF THESE GUIDELINES
There are four overarching aims of the guidelines: (1) to promote and
ensure proper collection of high-quality research specimens such that
each patient diagnosed with breast cancer can have a reliable, inter-
pretable molecular diagnosis; (2) to provide a known baseline of
standardization of specimen collection and handling procedures, to
the extent possible, such that more global biomarker analysis across
studies is possible; (3) to promote specimen collection that would
allow for future technologies, particularly in the molecular arena, to be
applied to these specimens for research; and (4) to provide guidelines
that group trial leadership can incorporate into clinical trial protocols.
It should be noted that each clinical trial protocol should stress
the importance of processing specimens in adherence to a standard-
ized set of procedures. Furthermore, adequate patient consent and
institutional review board approval for research on specimens is a
prerequisite for all specimen collection described herein. Finally, uni-
versal precautions apply to all handling of human specimens: Human
specimens should be handled as infectious agents (although FFPE
tissue can be shipped through regular mail).
INFORMATION GATHERING FOR THESE GUIDELINES
Three working groups—a blood, serum, and plasma; FFPE; and fresh/
frozen tissue—have met through many conference calls and one
face-to-face meeting to discuss best practices for specimen collection
and handling in group breast cancer trials. These working groups
included representatives from BIG, the North American Groups, the
National Cancer Institute (NCI) Cancer Therapy Evaluation Program
(CTEP) and Cancer Diagnosis Program (CDP), and the NCI Coop-
erative Group Banking Committee (GBC), which was formed by NCI
to develop specimen banking best practices for the North American
cooperative groups, across all cancers.
The working groups gathered information on the standard oper-
ating procedures (SOPs) of the specimen repositories of various North
American and international groups through collecting group bank
SOPs and administering a questionnaire to the GBC’s Best Practices
and Operations Subcommittee and BIG. The questionnaires shown in
Figures 1 and 2 cover the following areas:
● Procurement methods for fresh, frozen, and fixed solid tissue
● Procurement methods for blood components (for serum,
plasma, peripheral-blood mononuclear cells [PMBCs], DNA,
and RNA)
● Level of detail of annotation kept on how a sample was actu-
ally handled, especially time elapsed from extirpation to freez-
ing, reagents and fixatives used, and duration and temperature
of fixation
● Actions required at the local site (eg, centrifugation, aliquoting)
● Processing methodology for nucleic acid extraction from
solid tissue and blood; cell sorting from blood; tissue microar-
ray; and quality assurance (QA)
● Storage of nucleic acid, FFPE blocks, unstained slides, shav-
ings, fresh/frozen tissue, whole blood, serum, plasma, PBMC,
DNA, and RNA
● Data linkage procedures for linking information on speci-
mens to the clinical trial database
● Shipping from the collection site to the central repository
The data gathered from this questionnaire, from a comparison of
the submitted group banking SOPs, and from the working groups’
deliberations have been incorporated into these guidelines. A list of the
groups who submitted questionnaires appears in the Appendix (on-
line only).
SPECIMEN ACCESS AND USE
Central Banking of and Access to
Research Specimens
Specimens from a clinical trial, particularly FFPE tissues, must be
consolidated in a central bank independent from industry. Centraliza-
tion of specimens will greatly facilitate access to specimens by investi-
gators with meritorious proposals for specimen-based studies. Each
central bank should have a disaster policy in place with details for
carrying out this plan provided in the manual of operation.
The “honest broker” and “safe harbor” systems provide a high
level of comfort to member sites, institutional pathologists, and pa-
tients. These intrinsic measures ensure confidentiality and privacy
while providing researchers with necessary information and high-
quality samples. Independence from industry is important because
efforts by industry to claim intellectual property or other rights to
research specimens may compromise research.
Intellectual property issues related to clinical trial tissue banks
must be considered because many trials groups, particularly outside of
the cooperative groups, are not legal entities and cannot own or
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govern such intellectual property. A material transfer agreement
(MTA) that clearly identifies who owns the biologic material and its
associated intellectual property is an important component of any
specimen repository.
Researchers should be able to submit proposals for use of clinical
trial specimens (which would include tissue microarray sections). The
limited quantity and high value of clinical trial specimens warrant
their careful and triaged use. A committee should be in place, or
established, using prespecified policies, to vet proposals to prioritize
specimen usage appropriately, and to screen out proposals that are
without merit or that contain serious drawbacks.
International Trials
A central tissue bank should be established for each trial, with
custodianship vested in the trial’s steering group. An educational push
is needed among international clinical trial groups for sites to send in
Tissue Procurement
Type
Fresh
(for culture)
Frozen
Fixed
Collection
buffer
(eg, RPMI,
RNAlater,
formalin)
Collection
devices
(eg, punchers,
capsules, molds)
Variety
(eg, slides,
cores, block,
shaving)
Shipping kit
& method of
shipment
(eg, IATA
completed
shipper)
(e.g., slides,
cores, block,
shaving)
Time before
freezing
Do you specify a
time limit within
which the sample
must be frozen? If
so, what is that
time limit?
                     Tissue annotation
Please indicate the types of/level of detail of 
annotation kept on how a sample was 
actually handled. Especially, do you collect 
the following?
1) “How long before freezing”
2) “Reagents/fixatives used”
3) “Duration of fixation”
4) Temperature
5) Other info?
Additional Useful Info: Please include below any additional useful information you would like to provide on your Group’s solid tissue procurement 
and handling that you did not address above:
Tissue Processing Methods
TMA
Do you re-embed multi-site donor blocks?  Yes _______   No _______ 
Do you include cell-line/control tissue in final TMA?  Yes _______   No _______ 
How many cores do you include on a single TMA block? _______ 
Do you include replicate cores on the TMA? _______   If so, on same block or different blocks and how many?: ______________________________________
What size core do you include on the TMA? _______ 
What density of cores do you use on the TMA? _______ 
Do you take an extra core for nucleic acid extraction? _______ 
Do you take cores for TMAs before processing of FFPE tissue for RNA extraction? _______ 
Any addition information on your TMA methodology? __________________________________________________________________________________________
Nucleic Acid Extraction
Please list methods used for nucleic acid extraction (including kit names): ________________________________________________________________________
Do you extract nucleic acid up front, or do you store tissue for later extraction? ___________________________________________________________________
Any addition information on your nucleic acid extraction methodology? _________________________________________________________________________
Quality Assurance Procedures Measures
FFPE tissue: __________________________________________________________________________________________________________________________________
Fresh/frozen tissue ___________________________________________________________________________________________________________________________
Nucleic acid? (including quantification) ________________________________________________________________________________________________________
Storage Methods and General Conditions
Nucliec Acid _________________________________________________________________________________________________________________________________
Blocks _______________________________________________________________________________________________________________________________________
Unstained Slides _____________________________________________________________________________________________________________________________
Shavings ____________________________________________________________________________________________________________________________________
Frozen Tissue ________________________________________________________________________________________________________________________________
Fig 1. Quick questionnaire on group specimen collection, handling, and processing practices. IATA, International Air Transport Association; TMA, tissue microarray;
FFPE, formalin fixed, paraffin embedded; QA, quality assurance.
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biologic material for research, and then to centralize those bio-
logic materials.
North American Trials
In North America, specimens for a given trial should be central-
ized at the level of the group leading the trial; this also pertains to
specimens from intergroup trials. Retrospective as well as prospec-
tive consolidation of intergroup specimens is important to enable
research to be carried out on those specimens. Especially, intergroup
specimens from closed trials that are still stored at various groups or at
various sites need to be consolidated in the lead group’s bank.
FACILITIES, EQUIPMENT, AND SPACE
Common procedures for the collection of clinical trial specimens are
compounded by the variable differences in the facilities, equipment,
and expertise in personnel of the institutions submitting specimens.
Blood and Blood Component Procurement
Type
Local site
action
(eg, spin
and aliquot
Ficol, etc.)
Collection
devices
(eg, SST,
purple top,
PAXgene, etc.)
Shipping kits
provided
(eg, IATA,
ICAO 
compliant
shipper)
Method of
shipment
(eg, dry ice,
cold packs, etc.)
Time before
freezing
For those samples 
that need freezing, 
do you specify 
a time limit
within which the
sample must be
frozen? If so, what 
is that time limit?
                    Sample annotation
Please indicate the types of/level of detail of 
annotation kept on how a sample was 
actually handled. Especially, do you collect 
the following?
1) “How long before freezing”
         where applicable)
2) Temperature
3) Other info?
Additional Useful Info: Please include below any additional useful information you would like to provide on your Group’s blood/blood component 
procurement and handling that you did not address above:
Processing
Extraction Methods
DNA ________________________________________________________________________________________________________________________________________
RNA _________________________________________________________________________________________________________________________________________
Cell sorting __________________________________________________________________________________________________________________________________
Quality Assurance
Please describe your quantification and qualification/evaluation methods for the above: __________________________________________________________
Storage Methods and Conditions
Whole blood _________________________________________________________________________________________________________________________________
Serum _______________________________________________________________________________________________________________________________________
Plasma ______________________________________________________________________________________________________________________________________
PBMC _______________________________________________________________________________________________________________________________________
DNA ________________________________________________________________________________________________________________________________________
RNA _________________________________________________________________________________________________________________________________________
Data linkage
Do you have a procedure for linking information on specimens to the clinical trial database? _____ If so, which system do you use? _______
Standard Operating Procedures
If you have not sent these to Rebecca already, please attach the SOP(s) for specimen collection and handling used by your Group’s PCO/specimen 
bank, preferably (although not necessarily) for breast cancer trials. If this will take some time, please complete this questionnaire first and send this to 
Rebecca at renos@emmes.com, followed by the SOPs once those have been gathered.
Thank you for your time!
Serum
Plasma
PBMC
DNA
RNA
Fig 2. Fluid specimen questionnaire. SST, serum separator tube; IATA, International Air Transport Association; ICAO, International Civil Aviation Organisation; PBMC,
peripheral-blood mononuclear cell; SOP, standard operating procedure; PCO, Pathology Coordinating Office.
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Specimen processing variability at submitting institutions can result in
considerable heterogeneity in specimen likeness and quality.1-5 Bio-
specimen policy reviewing committees have concluded that efforts to
harmonize specimen processing at institutional levels is a significant
area of importance to improve the clinical trial specimen bank inven-
tory.7 Additional guidelines reported in the NCI Best Practices for
Biospecimens Resources6 and the International Society for Biological
and Environmental Repositories Best Practices for Repositories8 also
include comments on facilities and equipment.
PATHOLOGIST SUPPORT FOR SUBMITTING
RESEARCH SPECIMENS
Inconsistencies in how pathologists are engaged in the clinical trial at
the institutional level can greatly affect the consistency of specimen
submission. Does the pathologist specifically know the trial and the
specimen submission requirements? Will the pathologist provide time
and effort to screen the best or acceptable material requested by the
specimen submission requests of the trial? Is there established willing-
ness through fee-for-service to the pathology department, academic
credit, or official scientific engagement as part of a funded grant to
secure the pathologist’s effort? A great need exists to increase support
for pathologists and their associates, who carry the major workload
associated with submitting research tissue specimens.
FFPE RECOMMENDATIONS
Do policies in the pathology department fit the needs of the clinical
trial or can they be arranged to accommodate trial requirements?
Many pathology groups have instituted policies to not provide paraf-
fin blocks. More often, tissue sections are provided. However, tissue
sections are no longer desired for correlative science because of the
potential loss or degradation of biomarkers of interest, especially if the
period from sectioning to the time of analysis is greater than days or
weeks, which is often the situation in long-accruing trials. More ap-
propriately, paraffin tissue blocks, which patients consent to be used in
research, are the acceptable requirement. Policies should be developed
to accommodate FFPE tissue block submission when future clinical
needs of the existing FFPE block(s) are no longer indicated. However,
when there are few or single paraffin blocks as part of the clinical
record of the patient, then tissue cores should be the alternative to
tissue submission, provided that enough target tissue is available.
BLOOD, PLASMA, AND SERUM RECOMMENDATIONS
The common issues to procure quality blood, plasma, or serum center
on whether the specimens need to be processed expediently onsite by
the submitting institution or whether stability in the blood compo-
nents can survive the transport process to a central laboratory for
processing. There are both positive and negative results in either of
these performance-based issues. When multiple institutions process
specimens, procedures become more variable, as will specimen end
products. The more time sensitive or detailed the specimen process
the more variable the product. For example, if serum or plasma is
required and this must be processed (centrifuged, removed, aliquoted,
and frozen) within 8 hours of phlebotomy, most laboratories can
manage this requirement well. However, if the specimens should be
processed within 2 hours of phlebotomy, the percentage of trial spec-
imens that fail to be processed in this timeline increases. The fact is that
some institutions manage this well and others do not. The best prac-
tice is to balance the use of laboratories that are accustomed to per-
forming these steps at any hour of the day or can quickly ship
specimens to central bank locations where standard procedures can be
better managed.
Other more complicated specimen processing procedures can be
problematic for clinical trials and should be distinguished and dis-
cussed with scientist and pathologist when protocols are being
developed. Education in the clinical trial development may be
needed. For example, isolation of PBMCs as opposed to buffy-coat
WBCs (WBCs), requires quite different processes and with much
greater expertise for PBMC compared with WBC preparations. Clin-
ical trial protocol developers and physician-scientists often inappro-
priately interchange these kinds of terms, but in fact, these specimens
represent significant differences in processing requirements. Whereas
academic institutions can be organized to perform PBMC isolations,
most community hospitals cannot. Unless these specimens can be sent
to a central processing location, more stringent requests for the collec-
tion of PBMCs limit specimen submission.
FRESH/FROZEN TISSUE RECOMMENDATIONS
Fresh/frozen tissue collection is susceptible to limited timelines for
acceptable collection. However, as long as the general principles of
rapid collection and freezing (or transfer to RNAlater), as well as
seamless integration with standard pathologic assessment are re-
spected, these collections can be accomplished. To determine if ac-
ceptable methods are being used, adopted methods should be
employed as evidence of careful QA and should demonstrate feasibil-
ity in a variety of practice settings. Fresh/frozen tissue QA data should
be completed and made available on submitted specimens within a
relatively short timeline to provide feedback on the ability of each
collecting site to submit quality specimens as well as to document that
the protocol procedures are meeting the expectations of the clini-
cal trial.
SPECIMEN COLLECTION KITS
Preassembled kits sent by the central group bank to sites can vastly
expedite as well as standardize the collection of good-quality speci-
mens from sites, reduce the variability in collection procedures, facil-
itate onsite processing (such as aliquoting), and increase compliance
with the protocol-stipulated collection. Group banks should use pre-
assembled collection kits to the broadest extent possible.
LABELING
Vials, including cryovials, should be labeled with the study name or
number, a specimen ID number that is linked to the subject’s study ID,
Leyland-Jones et al
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contents of the vial, and date of collection. The latter is especially
important if the sample is a serial specimen. The subject’s study ID
should not be on the vial unless patient confidentiality is determined
to be secured according to the clinical trial protocol.
Specific procedures for labeling specimens should clearly be de-
fined in the protocol. The central bank itself should have standardized
labeling (printed or written) for archiving samples, such as unique
sample IDs and/or barcodes. For specimens that will be placed into
frozen storage, information on the label should be able to withstand
80°C and not become illegible. Alcohol-based permanent markers
will smudge. Markers specifically made for cryotemperatures are rec-
ommended instead.
All levels of receptacles containing the specimen should be la-
beled, from the smallest unit (eg, tube), to large storage units. Labeling
should be resistant to cold, solvents, and water (eg, cryomarker, cold-
resistant label, waterproof and solvent-proof pen).
The information included on a sample label must not include
patient identifying information, and should be compliant with the
Health Insurance Portability and Accountability Act (HIPAA). The
information should be sufficiently specific such that the encoded
information (eg, tracking number) can be linked to the sample in
the database.
SHIPPING
In addition to the following recommendations, please also see the
recommendations on shipping contained in the NCI Best Practices for
Biospecimens Resources, under Section B.1.5, Shipping Samples,
found on page 6 of that document.6
Shipping personnel must receive training and be certified for
biologic specimen shipping. Before choosing a courier for frozen
tissue, ensure that they (1) handle dry ice shipments and (2) service the
town or city in which the central bank is located. Dry ice should not be
shipped with couriers who have extremely restrictive policies concern-
ing shipments of hazardous materials.
For international studies, each country should consider iden-
tifying a tissue bank where tissue can be held before final shipping
to a central bank across borders. A site should consult the central
bank to determine the best times to ship samples that are frozen.
This will help to avoid inadvertent thawing caused by the evapora-
tion of dry ice.
Ideally, the central bank will have included shipping materials
in a kit sent to the collection site. Batch shipping of samples will
help to reduce the time required for organizing shipments and, in
the case of frozen samples, dry-ice shipping costs. A good guideline
for the interval of time between procurement and shipment is
1 month.
PACKAGING FOR ALL SPECIMENS
Packaging should comply with International Air Transport Associa-
tion (IATA) criteria (http://www.iata.org). If ground overnight is used
for FFPE samples, then shipment should conform to ground trans-
portation standards (eg, Department of Transportation packaging
standards, if in the US). The shipping box should be secured and
appropriate stickers should be placed, such as “Biologic Substance,
Category B UN 3373,” and the type of shipment (eg, next day). The
IATA shipping category appropriate to the specimens collected should
be used, both in labeling and in the training required for packaging. In
addition to “Biologic Substance, Category B,” other IATA categories
include “Exempt Human Specimens” and “Infectious Substance, Cat-
egory A.”
Consult the latest IATA regulations to determine which cate-
gory best applies to the specimens. Do not write the term “diagnos-
tic specimens” on the box: revision of the IATA regulations has
replaced the term “diagnostic specimens” with “Biologic Sub-
stance, Category B.” Biologic substances and specimens are subject
to specific packaging requirements and there should be no misun-
derstanding about the contents of the shipment, particularly with
regard to risk for infection of humans or animals. A completed
material submission form from the trial needs to be submitted
along with the specimens.
CONCLUSION
This article reflects time, effort, and experience from a substantial
number of contributors during the last 3 years. It reflects the impor-
tance of deriving unified standards for specimen collection in global
clinical trials; indeed it represents the first attempt at such a process. All
three committees (blood, plasma, and serum; fresh/frozen tissue; and
FFPE) comprise international participation; the extent of detail in the
SOPs tries to embrace the diversity of multinational approaches to the
same problems.
Key participants are committed to semi-annual meetings to for-
mally update the recommendations herein. However, all of the key
participants are requested to update the Web site of any important
advances/policy changes in real time. Hence, the Web site should
reflect the latest state-of-the-art specimen collection policies at any
given moment.
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